BCAX
Bicara Therapeutics Inc. Common StockHealthcare · $1.2B market cap
Verdict
We can't put a fair value on BCAX right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow BCAX
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 8, 2026: no open-market purchases, 2 sales worth $401K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Cohlhepp Ryan
President, COO & Interim CEO · 2026-09-08
Sold
$81K
Cohlhepp Ryan
President, COO & Interim CEO · 2026-09-08
Sold
$320K
Other filings
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works